MedPath

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

458

Active:234
Completed:175

Trial Phases

4 Phases

Phase 1:226
Phase 2:58
Phase 3:98
+1 more phases

Drug Approvals

6

NMPA:6

Drug Approvals

Deutetrabenazine Tablets

Product Name
安泰坦
Approval Number
国药准字HJ20200014
Approval Date
Sep 30, 2024
NMPA

Deutetrabenazine Tablets

Product Name
安泰坦
Approval Number
国药准字HJ20200013
Approval Date
Sep 30, 2024
NMPA

Deutetrabenazine Tablets

Product Name
安泰坦
Approval Number
国药准字HJ20200015
Approval Date
Sep 30, 2024
NMPA

Deutetrabenazine Tablet

Product Name
安泰坦
Approval Number
H20200015
Approval Date
May 12, 2020
NMPA

Deutetrabenazine Tablet

Product Name
安泰坦
Approval Number
H20200013
Approval Date
May 12, 2020
NMPA

Deutetrabenazine Tablet

Product Name
安泰坦
Approval Number
H20200014
Approval Date
May 12, 2020
NMPA

Clinical Trials

Distribution across different clinical trial phases (397 trials with phase data)• Click on a phase to view related trials

Phase 1
226 (56.9%)
Phase 3
98 (24.7%)
Phase 2
58 (14.6%)
Phase 4
15 (3.8%)

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Phase 2
Recruiting
Conditions
Celiac Disease
Interventions
Drug: Placebo
First Posted Date
2025-02-04
Last Posted Date
2025-06-26
Lead Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Target Recruit Count
48
Registration Number
NCT06807463
Locations
🇺🇸

Teva Investigational Site 12133, Marrero, Louisiana, United States

🇺🇸

Teva Investigational Site 12131, Colorado Springs, Colorado, United States

🇺🇸

Teva Investigational Site 12134, Inverness, Florida, United States

and more 9 locations

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older with Asthma

Phase 3
Not yet recruiting
Conditions
Asthma
First Posted Date
2025-06-04
Last Posted Date
2025-06-10
Lead Sponsor
Teva Branded Pharmaceutical Products R&D Inc.
Target Recruit Count
555
Registration Number
2024-517991-39-00
Locations
🇵🇱

Synexus Polska Sp. z o.o., Gdansk, Poland

🇵🇱

Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o., Tarnow, Poland

🇵🇱

Santa Sp. z o.o., Lodz, Poland

and more 26 locations

Mass Balance Clinical Trial With TEV-56286

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: [14C]-TEV-56286
First Posted Date
2024-10-04
Last Posted Date
2025-01-29
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
8
Registration Number
NCT06627231
Locations
🇳🇱

Teva Investigational Site 38189, Groningen, Netherlands

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Phase 1
Recruiting
Conditions
Vitiligo
Interventions
First Posted Date
2024-10-03
Last Posted Date
2025-06-05
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
28
Registration Number
NCT06625177
Locations
🇺🇸

Teva Investigational Site 12043, Scottsdale, Arizona, United States

🇺🇸

Teva Investigational Site 12052, Hot Springs, Arkansas, United States

🇺🇸

Teva Investigational Site 12044, Fremont, California, United States

and more 8 locations

A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy

Phase 2
Recruiting
Conditions
Multiple System Atrophy
First Posted Date
2024-04-16
Last Posted Date
2025-05-26
Lead Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Target Recruit Count
103
Registration Number
2023-505320-54-00
Locations
🇫🇷

Assistance Publique Hopitaux De Paris, Paris Cedex 13, France

🇫🇷

Centre Hospitalier Universitaire De Bordeaux, Bordeaux, France

🇫🇷

Centre Hospitalier Universitaire De Toulouse, Toulouse, France

and more 25 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 44
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath